0001193125-24-156678.txt : 20240607 0001193125-24-156678.hdr.sgml : 20240607 20240607073102 ACCESSION NUMBER: 0001193125-24-156678 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240605 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240607 DATE AS OF CHANGE: 20240607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIORA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001580063 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273950390 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39334 FILM NUMBER: 241027377 BUSINESS ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 855-293-2639 MAIL ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: PROGENITY, INC. DATE OF NAME CHANGE: 20150617 FORMER COMPANY: FORMER CONFORMED NAME: ASCENDANT MDX, INC. DATE OF NAME CHANGE: 20130625 8-K 1 d846643d8k.htm 8-K 8-K
false 0001580063 --12-31 0001580063 2024-06-05 2024-06-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2024

 

 

Biora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39334   27-3950390
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

4330 La Jolla Village Drive, Suite 300  
San Diego, California   92122
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (833) 727-2841

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   BIOR   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Biora Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) on June 5, 2024 at 10:00 a.m. Pacific Time. As of the close of business on April 16, 2024, the record date for the Annual Meeting, there were 35,883,843 shares of common stock entitled to vote at the meeting.

 

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”) to increase the number of authorized shares of Common Stock from 164,000,000 to 300,000,000 and to increase the total number of authorized shares from 174,000,000 to 310,000,000 (the “Amendment”).

On June 5, 2024, the Company filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Amendment, which became effective immediately upon such filing.

The foregoing description of the Amendment does not purport to be complete and is subject to and qualified in its entirety by reference to the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1, and is incorporated herein by reference.

 

Item 5.07

Submission of Matters to a Vote of Security Holders

Stockholders voted on the following proposals at the Annual Meeting:

 

  1.

The following director nominees were elected to serve until the 2025 Annual Meeting of Stockholders based upon the following votes:

 

Nominee

  

Votes For

  

Votes Withheld

  

Broker Non-Votes

Adi Mohanty

   15,140,932   965,503   7,677,992

Jeffrey D. Alter

   15,242,112   864,323   7,677,992

Jeffrey A. Ferrell

   15,198,546   907,889   7,677,992

Jill Howe

   15,289,911   816,524   7,677,992

Brian L. Kotzin, M.D.

   15,280,909   825,149   7,678,369

Lynne Powell

   15,290,962   815,473   7,677,992

 

  2.

The selection of KPMG LLP as the Company’s independent registered public accounting firm for 2024 was ratified as follows:

 

Votes For

  

Votes Against

  

Abstentions

  

Broker Non-Votes

22,573,239

   1,095,347   115,841   0

 

  3.

The amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 164,000,000 to 300,000,000 was approved as follows:

 

Votes For

  

Votes Against

  

Abstentions

  

Broker Non-Votes

14,569,807

   1,512,454   24,174   7,677,992

 

  4.

The issuance, for purposes of complying with Nasdaq Listing Rule 5635(d), of shares of common stock underlying certain warrants issued by the Company pursuant to that certain Securities Purchase Agreement, dated as of March 31, 2024, by and among the Company and certain institutional and accredited investors, and those certain Warrant Amendment Agreements, dated as of March 31, 2024, by and between the Company and the institutional investors participating in the offering, in an amount equal to or in excess of 20% of the common stock outstanding immediately prior the issuance of such warrants was authorized as follows:

 

Votes For

  

Votes Against

  

Abstentions

  

Broker Non-Votes

13,373,863

   1,227,314   1,396,848   7,786,402

 

Item 9.01

Financial Statements and Exhibits

 

(d)

Exhibits

 

3.1    Third Certificate of Amendment to Eighth Amended and Restated Certificate of Incorporation of Biora Therapeutics, Inc.
104    Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 7, 2024     Biora Therapeutics, Inc.
    By:  

/s/ Eric d’ Esparbes

      Eric d’ Esparbes
      Chief Financial Officer
 EX-3.1 2 d846643dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

THIRD CERTIFICATE OF AMENDMENT TO EIGHTH AMENDED AND

RESTATED CERTIFICATE OF INCORPORATION OF

BIORA THERAPEUTICS, INC.

Biora Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows:

 

  1.

The current name of the Corporation is Biora Therapeutics, Inc., and the Corporation was originally incorporated pursuant to the General Corporation Law on January 9, 2012 under the name Ascendant MDx, Inc.

 

  2.

The Corporation’s Eighth Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on June 23, 2020 (as amended from time to time, the “Certificate of Incorporation”).

 

  3.

The amendments to the Certificate of Incorporation set forth in this Certificate of Amendment were duly authorized and adopted in accordance with Section 242 of the General Corporation Law.

 

  4.

The amendments to the existing Certificate of Incorporation being effected hereby are to amend and restate in its entirety Section 4.1(a) of Article IV of the Certificate of Incorporation to read as follows:

“(a) Authorized Stock. The total number of shares which the Corporation shall have authority to issue is 310,000,000, of which 300,000,000 shall be designated as Common Stock, par value $0.001 per share (the “Common Stock”), and 10,000,000 shall be designated as Preferred Stock, par value $0.001 per share (the “Preferred Stock”).”

 

  5.

This Certificate of Amendment to the Certificate of Incorporation shall be effective immediately upon filing with the Secretary.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to the Certificate of Incorporation to be signed by its Senior Vice President, General Counsel & Secretary this 5th day of June 2024.

 

By:   /s/ Clarke Neumann
  Clarke Neumann
  Senior Vice President, General Counsel & Secretary

 

1

EX-101.SCH 3 bior-20240605.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 bior-20240605_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 bior-20240605_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 05, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001580063
Current Fiscal Year End Date --12-31
Document Type 8-K
Document Period End Date Jun. 05, 2024
Entity Registrant Name Biora Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39334
Entity Tax Identification Number 27-3950390
Entity Address, Address Line One 4330 La Jolla Village Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code (833)
Local Phone Number 727-2841
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol BIOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bior-20240605.xsd bior-20240605_lab.xml bior-20240605_pre.xml d846643d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d846643d8k.htm": { "nsprefix": "bior", "nsuri": "http://bioratherapeutics.com/20240605", "dts": { "schema": { "local": [ "bior-20240605.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "bior-20240605_lab.xml" ] }, "presentationLink": { "local": [ "bior-20240605_pre.xml" ] }, "inline": { "local": [ "d846643d8k.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-05_to_2024-06-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d846643d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-05_to_2024-06-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d846643d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bioratherapeutics.com//20240605/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-24-156678-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-156678-xbrl.zip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d846643d8k_htm.xml IDEA: XBRL DOCUMENT 0001580063 2024-06-05 2024-06-05 false 0001580063 --12-31 8-K 2024-06-05 Biora Therapeutics, Inc. DE 001-39334 27-3950390 4330 La Jolla Village Drive Suite 300 San Diego CA 92122 (833) 727-2841 false false false false Common Stock, par value $0.001 per share BIOR NASDAQ true false